Join the RSV Vaccine, Pref A-Pref B, Recombinant group to help and get support from people like you.
RSV Vaccine, Pref A-Pref B, Recombinant News
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 – Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7...
72 Percent of Infants Immunized Against Respiratory Syncytial Virus
TUESDAY, May 6, 2025 – In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory syncytial virus (RSV)....
Eight in 10 Infants Received RSV Protection in the 2023 to 2024 Season
WEDNESDAY, Jan. 8, 2025 – Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published online Jan. 8 in JAMA ...
FDA Medwatch Alert: FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy
ISSUE: FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc. and Arexvy (Respiratory...
Immunocompromised Have Heterogeneous Antibody Response to RSV Vaccines
TUESDAY, Jan. 7, 2025 – For immunocompromised individuals, antibody response to respiratory syncytial virus (RSV) vaccines is heterogeneous and about 40 percent do not seroconvert, according to a...
Confidence in Vaccines Both Steady and Rising in U.S. Adults
THURSDAY, Jan. 2, 2025 -- Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more widely accepted by the American public, while confidence in other ...
Has RSV Vaccine Hesitancy Subsided?
FRIDAY, Dec. 27, 2024 – More Americans believe in the effectiveness of vaccines developed to protect newborns and seniors against respiratory syncytial virus (RSV). More than half of U.S. adults...
RSV Burden Remains High in Young Children in the United States
WEDNESDAY, Dec. 11, 2024 – The burden of respiratory syncytial virus (RSV) in young children continues to be high in the United States, according to a study published online Dec. 9 in JAMA...
COVID-19, Flu, RSV Vaccine Coverage Low for Nursing Home Residents
TUESDAY, Nov. 26, 2024 – COVID-19, influenza, and respiratory syncytial virus (RSV) vaccination coverage is low among nursing home residents early in the 2024 to 2025 season, according to research...
Study Assesses Risk for 28-Day Hospitalization for Adults With RSV
WEDNESDAY, Nov. 20, 2024 – A number of adults with outpatient medically attended respiratory syncytial virus (MA-RSV) infection experience hospitalization within 28 days, with a higher proportion...
Optimal Timing of Maternal RSV Vaccine Determined to Be at Least Five Weeks Before Delivery
THURSDAY, Nov. 21, 2024 – Respiratory syncytial virus (RSV) vaccination at least five weeks prior to delivery results in the highest transplacental transfer of maternal antibodies to the neonate,...
RSV Hospitalizations Linked to Considerable Burden in Adults
FRIDAY, Nov. 15, 2024 – Respiratory syncytial virus (RSV) is associated with a considerable burden of hospitalizations, intensive care unit (ICU) admissions, and in-hospital deaths among adults,...
RSV Vaccination Prevents Associated Hospitalization, Emergency Encounters
THURSDAY, Nov. 7, 2024 – For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters,...
Monthly News Roundup - October 2024
FDA Approves AbbVie’s Vyalev to Treat Advanced Parkinson Disease In October, the US Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) for the treatment of motor f...
U.S. FDA Approves Pfizer’s RSV Vaccine Abrysvo for Adults Aged 18 to 59 at Increased Risk for Disease
NEW YORK--(BUSINESS WIRE) October 22, 2024 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the...